Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 153) Show all publications
Vyakaranam, A. R., Norlén, O., Akural, A., Crona, J., Annebäck, M., Klimàcek, B., . . . Åkerström, T. (2026). 11C-Hydroxyephedrine PET/CT for preoperative surgical planning in large pheochromocytoma and paraganglioma.. Journal of neuroendocrinology, 38(1), Article ID e70121.
Open this publication in new window or tab >>11C-Hydroxyephedrine PET/CT for preoperative surgical planning in large pheochromocytoma and paraganglioma.
Show others...
2026 (English)In: Journal of neuroendocrinology, ISSN 0953-8194, E-ISSN 1365-2826, Vol. 38, no 1, article id e70121Article in journal (Refereed) Published
Abstract [en]

Early detection of metastases and timely surgical intervention play a crucial role in the management of neuroendocrine tumors. In large-sized pheochromocytomas and sympathetic paragangliomas (PPGL), functional imaging with positron emission tomography (PET) is recommended, as it improves the detection of metastases, which may go undetected on conventional radiologic imaging. 11C-hydroxyephedrine binds to the norepinephrine transporter receptor and is detected by PET/CT (HED-PET/CT). It has previously demonstrated high accuracy in detecting primary and metastatic PPGL; however, its impact on preoperative staging is unclear. In this study, we retrospectively analyzed a selected cohort of 44 patients with large PPGL to evaluate whether HED-PET/CT influences preoperative clinical decision-making. All patients who underwent HED-PET/CT at Uppsala University Hospital between 2004 and 2024 were screened for inclusion. In total, 44 patients with pheochromocytomas >5 cm and paragangliomas >4 cm were included. HED-PET/CT results were compared with CT/MR findings, and a final consensus was reached on whether preoperative HED-PET/CT would have altered clinical decision-making. HED-PET/CT identified previously undetected metastatic disease in three patients (6.8%), which had not been visualized on CT/MR. Additionally, two patients had discordant findings, where HED-PET/CT revealed additional metastases. In one case, a liver metastasis was identified postoperatively with HED-PET/CT, leading to a metastasectomy that could have potentially been avoided. These findings suggest that HED-PET/CT is highly accurate in detecting metastases; however, its routine preoperative use may be limited and appears to provide significant clinical benefit only in selected patients.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
11C‐hydroxyephedrine PET/CT, paraganglioma, pheochromocytoma
National Category
Surgery
Identifiers
urn:nbn:se:uu:diva-576038 (URN)10.1111/jne.70121 (DOI)001627786600001 ()41319260 (PubMedID)2-s2.0-105023540218 (Scopus ID)
Available from: 2026-01-14 Created: 2026-01-14 Last updated: 2026-03-19Bibliographically approved
Stålberg, P., McNamara, M. G., Grozinsky-Glasberg, S., Pascher, A., Kos-Kudla, B., Denecke, T., . . . Baudin, E. (2026). Controversies in NEN: An ENETS position statement on the role of liver transplantation (LT) in patients with advanced small-intestinal and pancreatic NETs. Journal of neuroendocrinology, 38(10), Article ID e70250.
Open this publication in new window or tab >>Controversies in NEN: An ENETS position statement on the role of liver transplantation (LT) in patients with advanced small-intestinal and pancreatic NETs
Show others...
2026 (English)In: Journal of neuroendocrinology, ISSN 0953-8194, E-ISSN 1365-2826, Vol. 38, no 10, article id e70250Article in journal (Refereed) Published
Abstract [en]

Liver transplantation (LT) may offer survival or symptomatic benefit for highly selected patients with advanced, well-differentiated small-intestinal or pancreatic neuroendocrine tumours and unresectable liver-dominant metastases. However, its role remains controversial, as LT is rarely curative, recurrence is common, and benefits must be weighed against perioperative risk, lifelong immunosuppression, alternative therapies, and organ allocation ethics. This ENETS position statement summarises current evidence and expert consensus, reframing LT within a transplant-benefit model rather than fixed eligibility criteria. It outlines biologically informed selection principles and multidisciplinary assessment, as well as addressing the need for standardised characterisation, prospective registries, and long-term outcome data to better define the net clinical benefit of LT in this rare patient population.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
ENETS, gastroenteropancreatic neuroendocrine tumours, guidance/guidelines/controversies, liver transplantation
National Category
Endocrinology and Diabetes Surgery Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-601838 (URN)10.1111/jne.70250 (DOI)001892755700001 ()42816382 (PubMedID)2-s2.0-105052109518 (Scopus ID)
Available from: 2026-10-22 Created: 2026-10-22 Last updated: 2026-10-22Bibliographically approved
Partelli, S., Bartsch, D. K., Falconi, M., Grossman, A., Knigge, U., Langer, S. W., . . . Tiensuu Janson, E. (2026). Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours. Journal of neuroendocrinology, 38(3), Article ID e70156.
Open this publication in new window or tab >>Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours
Show others...
2026 (English)In: Journal of neuroendocrinology, ISSN 0953-8194, E-ISSN 1365-2826, Vol. 38, no 3, article id e70156Article in journal (Refereed) Published
Abstract [en]

The role of primary tumour resection (PTR) in metastatic small intestinal (SiNETs) and pancreatic neuroendocrine tumours (PanNETs) remains debated. While retrospective studies suggest improved survival and possible reduction of local complications, the evidence is limited by heterogeneity, selection bias, and an absence of prospective validation. Under the auspices of the European Neuroendocrine Tumor Society (ENETS) Advisory Board, this position paper summarises current knowledge and expert consensus on the rationale, potential benefits, patient selection, timing, integration with systemic therapies, and future perspectives for PTR. PTR may be considered in selected patients with liver-limited or liver-dominant disease, indolent tumour biology, and good performance status, especially to prevent obstruction, bleeding, or ischaemia, to reduce symptomatic tumour burden, or to facilitate systemic and liver-directed therapies. However, the risks of major surgery, including intestinal and pancreatic resections, with long-term impact on digestion and nutrition, must be carefully considered. Decisions should be made in dedicated multidisciplinary tumour boards. Future directions include incorporation of molecular biomarkers, functional imaging, tumour growth rate, radiomics, and real-world data to refine patient selection. Quality of life and patient-reported outcomes remain underexplored and should be co-primary endpoints in prospective studies. PTR should not currently be regarded as standard of care for all cases but may have a role in carefully selected patients within integrated and individualised management strategies.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
metastatic NETs, multidisciplinary management, pancreatic neuroendocrine tumours, primary tumour resection, small intestinal neuroendocrine tumours
National Category
Cancer and Oncology Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-583934 (URN)10.1111/jne.70156 (DOI)001720791900001 ()41856794 (PubMedID)2-s2.0-105033398183 (Scopus ID)
Available from: 2026-04-10 Created: 2026-04-10 Last updated: 2026-04-10Bibliographically approved
Backman, S., Axling, F., Zhang, L., Botling, J., Juhlin, C. C., Barazeghi, E., . . . Åkerström, T. (2026). Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma. Endocrine pathology, 37(1), Article ID 25.
Open this publication in new window or tab >>Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma
Show others...
2026 (English)In: Endocrine pathology, ISSN 1046-3976, E-ISSN 1559-0097, Vol. 37, no 1, article id 25Article in journal (Refereed) Published
Abstract [en]

The mechanisms underlying how adrenocortical carcinoma (ACC) progresses into a metastatic and lethal disease remain poorly understood. To address this, we performed comprehensive genomic analyses to delineate the evolutionary trajectory of advanced ACC. Fresh frozen tumour samples (n = 29) were obtained from nine patients, all of whom had matched primary and relapse specimens, including recurrent (n = 4) and metastatic (n = 11) lesions. In four patients, multiple primary and metastatic samples were available, enabling detailed evolutionary comparisons. All tumours underwent whole-genome sequencing, RNA sequencing, and DNA methylation profiling. Our analyses revealed that seven of nine patients exhibited global loss of heterozygosity (LOH) often followed by whole-genome doubling, resulting in copy-neutral LOH. SNP-based analyses indicated that these alterations occurred as a single catastrophic event that was conserved across all matched samples within each patient, suggesting that this event constitutes a truncal feature of the evolutionary tree. These results support a model in which chromosomal aneuploidy is important in ACC tumourigenesis, potentially distinguishing carcinomas from benign adrenal adenomas. This may explain the rarity of adenoma-to-carcinoma transformation and suggest a diagnostic and therapeutic relevance of chromosomal instability in ACC.

Place, publisher, year, edition, pages
Springer, 2026
Keywords
Adrenocortical carcinoma, Tumour evolution, Copy number alterations, Whole genome sequencing, Endocrine cancer
National Category
Cancer and Oncology Medical Genetics and Genomics
Identifiers
urn:nbn:se:uu:diva-591446 (URN)10.1007/s12022-026-09922-2 (DOI)001787998000001 ()42265438 (PubMedID)2-s2.0-105041284655 (Scopus ID)
Available from: 2026-06-22 Created: 2026-06-22 Last updated: 2026-06-22Bibliographically approved
Edholm, A., Li, S.-C., Chu, X., Wargelius, H.-L., Razmara, M., Widgren, A., . . . Skogseid, B. (2026). Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines. Endocrine-Related Cancer, 33(2), Article ID e250442.
Open this publication in new window or tab >>Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines
Show others...
2026 (English)In: Endocrine-Related Cancer, ISSN 1351-0088, E-ISSN 1479-6821, Vol. 33, no 2, article id e250442Article in journal (Refereed) Published
Abstract [en]

Adrenocortical carcinoma (ACC) is a devastating disease with few effective treatments. The underlying molecular pathways remain largely unknown. To identify potential pathways and drivers relevant to ACC pathogenesis, we utilized histologically normal adrenals from heterozygous multiple endocrine neoplasia type 1 (Men1) mice to study early adrenocortical tumorigenesis. Employing mass spectrometry-based proteomic profiling, we identified 681 proteins, of which 52 displayed significant differential regulation in the adrenal tissues of heterozygous Men1 mice in comparison with their wild-type counterparts. Among these were fatty acid synthase (FASN) and ATP-citrate lyase (ACLY), two enzymes previously shown to be upregulated in several other types of tumors. To assess the functional impact of ACLY and FASN in ACC, we used H295R cells as the primary model. Cells were treated with SB-204990 (ACLY inhibitor) or C75 (FASN inhibitor), which both showed a dose-dependent antiproliferative effect. Lipidomic analysis revealed a significant reduction in palmitic acid and palmitoleic acid in treated cells compared to controls, supporting a mechanistic link between ACLY/FASN activity and lipid biosynthesis. Finally, data from The Cancer Genome Atlas showed significantly diminished survival outcomes among ACC patients exhibiting high ACLY or FASN expression. These findings underscore the potential importance of exploring the inhibition of lipid synthesis as a promising avenue for further research in the context of human ACC.

Place, publisher, year, edition, pages
Bioscientifica, 2026
Keywords
MEN1, adrenocortical carcinoma, ACLY, FASN
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-583853 (URN)10.1530/ERC-25-0442 (DOI)001721439500005 ()41649571 (PubMedID)2-s2.0-105030760331 (Scopus ID)
Funder
Swedish Cancer Society, 20 1310 PjF
Available from: 2026-04-09 Created: 2026-04-09 Last updated: 2026-04-09Bibliographically approved
Olsson, F., Jangland, E., Norlén, O., Stålberg, P. & Edfeldt, K. (2026). Living in the shadow of uncertainty – in the light of possibility: a phenomenological study of living with metastatic small intestinal neuroendocrine tumour. European Journal of Oncology Nursing, 85, 103358-103358, Article ID 103358.
Open this publication in new window or tab >>Living in the shadow of uncertainty – in the light of possibility: a phenomenological study of living with metastatic small intestinal neuroendocrine tumour
Show others...
2026 (English)In: European Journal of Oncology Nursing, ISSN 1462-3889, E-ISSN 1532-2122, Vol. 85, p. 103358-103358, article id 103358Article in journal (Refereed) Published
National Category
Medical and Health Sciences Surgery Cancer and Oncology Nursing
Identifiers
urn:nbn:se:uu:diva-603229 (URN)10.1016/j.ejon.2026.103358 (DOI)
Funder
Uppsala UniversityUppsala University
Available from: 2026-11-11 Created: 2026-11-11 Last updated: 2026-11-11
Axling, F., Backman, S., Hellman, P., Norlén, O., Barazeghi, E. & Stålberg, P. (2026). Metformin inhibits small intestinal neuroendocrine tumor growth in vivo. BMC Cancer, 26(1), Article ID 772.
Open this publication in new window or tab >>Metformin inhibits small intestinal neuroendocrine tumor growth in vivo
Show others...
2026 (English)In: BMC Cancer, E-ISSN 1471-2407, Vol. 26, no 1, article id 772Article in journal (Refereed) Published
Abstract [en]

Background

Small intestinal neuroendocrine tumors (SI-NETs) are slow-growing but highly metastatic, with most patients presenting metastases at diagnosis. Radical surgery remains the only potential curative option when feasible. Consequently, there is a critical need for novel therapeutic strategies that can limit tumor progression and enable more personalized treatment approaches in combination with current clinical practices. In this study, we evaluated the impact of metformin on SI-NET cell growth in vivo, characterized the associated microRNA expression profile, and identified potential driver genes modulated by metformin treatment.

Methods

A total of 22 SI-NET xenograft mouse models were established using CNDT2.5 and GOT1 cells. Mice were treated with metformin (2.56 mg/mL in drinking water) or water as control for 4 weeks. To explore the molecular impact of metformin, both small-RNA and total-RNA sequencing were performed on the dissected xenograft tumors. Proliferation and apoptosis were further evaluated by immunohistochemistry.

Results

In vivo treatment of SI-NET cells with metformin led to a reduction in tumor size in both CNDT2.5 and GOT1 xenograft models. Our sequencing analyses identified seven altered microRNAs and 1,776 differentially expressed genes in metformin-treated tumors compared to controls. To uncover potential driver genes in SI-NETs affected by metformin, we compared the differentially expressed genes from GOT1 xenograft model with those identified by comparing single-cell RNA profile of enterochromaffin cells to SI-NETs. This novel approach revealed a set of significantly regulated genes, including those involved in tumor proliferation, apoptosis, and metastasis, as well as genes related to voltage-gated calcium channels and signal transduction.

Conclusions

Our novel findings support further investigation of metformin as a potential therapeutic agent in clinical trials for SI-NET patients, and suggest that identified miRNAs should be assessed as potential predictive biomarkers for metformin treatment. This study highlights novel candidate driver genes affected by metformin, which are associated with key cellular processes and enterochromaffin cell’s function, offering insights into the underlying mechanisms in SI-NETs.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2026
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-565522 (URN)10.1186/s12885-026-16418-z (DOI)001804208900002 ()42350991 (PubMedID)2-s2.0-105042731510 (Scopus ID)
Funder
Swedish Cancer Society
Note

Elham Barazeghi and Peter Stålberg contributed equally to this work.

Available from: 2025-08-22 Created: 2025-08-22 Last updated: 2026-07-13Bibliographically approved
Axling, F., Backman, S., Hellman, P., Norlén, O. & Stålberg, P. (2026). Methylation profiling reveals epigenetic programs associated with chr18 loss in small intestinal neuroendocrine tumors. Frontiers in Oncology, 16, Article ID 1885499.
Open this publication in new window or tab >>Methylation profiling reveals epigenetic programs associated with chr18 loss in small intestinal neuroendocrine tumors
Show others...
2026 (English)In: Frontiers in Oncology, E-ISSN 2234-943X, Vol. 16, article id 1885499Article in journal (Refereed) Published
Abstract [en]

Introduction: 

Small intestinal neuroendocrine tumors (SI-NETs) are characterized by a low mutational burden and limited recurrent driver mutations, suggesting that other mechanisms contribute to tumor development. One of the most frequent genomic alterations in SI-NETs is loss of heterozygosity on chromosome 18 (chr18del), which defines a major molecular subtype. However, the epigenetic consequences of this event remain poorly understood.

Methods: 

In this study, we used long-read whole-genome sequencing to characterize genome-wide DNA methylation patterns in twelve primary tumors. Native methylation detection and copy-number profiling enabled stratification of tumors according to chromosome 18 status and direct comparison of epigenetic states between chr18del and non-chr18del (diploid) tumors.

Results: 

Chr18del tumors displayed widespread hypomethylation relative to diploid tumors, while chromosome 18 showed spatially structured regional methylation differences, including localized regions of increased methylation. Cross-platform validation using an independent Illumina EPIC methylation cohort confirmed the direction and distribution of many methylation events. Integration with the corresponding transcriptomic dataset revealed that a subset of methylation changes was associated with differential gene expression consistent with established promoter- and gene-body methylation models. Functional categorization of these methylation states revealed regulatory patterns linked to neuronal signaling, intracellular signaling cascades, and interactions with the extracellular matrix.

Discussion: 

Together, these findings support an association between chromosome 18 status and widespread methylation differences that extend beyond the affected chromosome and are linked to transcriptional programs relevant to neuroendocrine tumor biology.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2026
Keywords
chromosome 18 loss, DNA methylation, epigenetics, long-read sequencing, small intestinal neuroendocrine tumors
National Category
Cancer and Oncology
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-565520 (URN)10.3389/fonc.2026.1885499 (DOI)001903047300001 ()42889170 (PubMedID)
Funder
Swedish Cancer Society
Available from: 2025-08-22 Created: 2025-08-22 Last updated: 2026-10-27Bibliographically approved
Axling, F., Barazeghi, E., Hellman, P., Norlén, O., Backman, S. & Stålberg, P. (2026). Single-Cell Comparison of Small Intestinal Neuroendocrine Tumors and Enterochromaffin Cells from Two Patients. Cancers, 18(3), 435-435
Open this publication in new window or tab >>Single-Cell Comparison of Small Intestinal Neuroendocrine Tumors and Enterochromaffin Cells from Two Patients
Show others...
2026 (English)In: Cancers, ISSN 2072-6694, Vol. 18, no 3, p. 435-435Article in journal (Refereed) Published
Abstract [en]

Background: Several studies have attempted to identify the initiating drivers of small intestinal neuroendocrine tumor (SI-NET) development and the molecular mechanisms underlying their progression and metastatic spread. Previous gene expression studies have used bulk microarrays or RNA sequencing to compare tumor tissue with normal intestinal mucosa. However, the intestine comprises multiple distinct cell types, and bulk analyses are limited by this cellular heterogeneity, which can confound tumor-specific signals.

Methods: We performed single-cell RNA sequencing on primary SI-NETs and paired normal mucosa from two patients to directly compare tumor cells with their cells of origin, the enterochromaffin (EC) cells. To minimize type I errors, we applied a two-step validation strategy by overlapping differentially expressed genes with an external single-cell dataset and cross-referencing candidate genes for enteroendocrine expression in the Human Protein Atlas.

Results: For further distinction and characterization, ECs were subdivided into serotonergic and non-serotonergic clusters. This analysis revealed that the SI-NET cells are transcriptionally more similar to serotonergic ECs, consistent with serum metabolite profiles derived from clinical parameters. Our analyses uncovered a loss-of-expression program characterized by regulators of epithelial differentiation and in parallel, a gain-of-expression program displayed neuronal signaling gene induction, implicating functional reprogramming toward neuronal-like properties. Together, these specific losses and gains suggest that our patient-derived SI-NETs undergo adaptation through both loss of enteroendocrine functions and acquisition of neurobiological-promoting signaling pathways.

Conclusions: These findings nominate candidate drivers for further functional validation and highlight potential therapeutic strategies in our patient cohort, including restoring suppressed Notch signaling and targeting aberrant neuronal signaling networks. However, even with a two-step validation procedure, the modest cohort size limits statistical power and generalizability, particularly for the proposed association to a serotonergic phenotype. Larger, multi-patient single-cell studies are required to confirm these mechanisms and establish their clinical relevance.

Place, publisher, year, edition, pages
MDPI, 2026
Keywords
neuroendocrine tumors, SI-NET, enterochromaffin cell, scRNA-seq, transcriptomics
National Category
Cancer and Oncology Cell and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-581111 (URN)10.3390/cancers18030435 (DOI)001687664300001 ()41681906 (PubMedID)2-s2.0-105030072680 (Scopus ID)
Note

Title in the list of papers of Fredrik Axling's thesis: A single-cell comparison between small intestinal neuro-endocrine tumors and their progenitor

Available from: 2026-03-02 Created: 2026-03-02 Last updated: 2026-09-04Bibliographically approved
Klimàcek, B., Åkerström, T., Annebäck, M., Hellman, P., Norlén, O. & Stålberg, P. (2025). Evaluation of hand-assisted laparoscopic surgery of small intestinal neuroendocrine tumours as an alternative surgical treatment to open surgery. Langenbeck's archives of surgery (Print), 410(1), Article ID 90.
Open this publication in new window or tab >>Evaluation of hand-assisted laparoscopic surgery of small intestinal neuroendocrine tumours as an alternative surgical treatment to open surgery
Show others...
2025 (English)In: Langenbeck's archives of surgery (Print), ISSN 1435-2443, E-ISSN 1435-2451, Vol. 410, no 1, article id 90Article in journal (Refereed) Published
Abstract [en]

Purpose Small intestinal neuroendocrine tumours (SI-NETs) are the most common malignancy of the small bowel. Curative treatment is surgical, with exploratory laparotomy considered the standard approach. This study aimed to assess the outcomes of minimally invasive surgery compared to open approach for SI-NETs at the Endocrine surgical unit at Uppsala University Hospital. Methods This retrospective cohort study included patients who underwent surgery for SI-NET between 2013 and 2023 at Uppsala University Hospital. Variables such as operative time, length of hospital stay, use of analgesia and radicality were compared between groups of patients operated on before and after 2019, when hand-port assisted laparoscopic surgery (HALS) for SI-NETs was introduced at our unit. Outcomes were further compared between open and hand-port assisted laparoscopic approaches. The primary outcome was the rate of radicality achieved for stage II-III patients. Secondary outcomes included operative time, the length of hospital stay and the use of epidural and patient-controlled analgesia. Results Of 97 patients, 58 (59.8%) underwent open surgery and 39 (40.2%) underwent hand-port assisted laparoscopic surgery. There was no significant difference in operative time (121 min [91.3-150.3] vs 108 min [83-141]), length of hospital stay, 6 days [4-7] vs 5 days [4-8]), and surgical radicality in patients with stage II-III, 85.2% vs 100%, (p = 0.079). 86.2% of patients with explorative laparotomy required epidural analgesia compared to only 23.1% with HALS (p < 0.001). Conclusion Hand-port assisted laparoscopic surgery of SI-NETs is a feasible approach that preserves radical resection while enhancing postoperative recovery, with a lower requirement of epidural analgesia.

Place, publisher, year, edition, pages
Springer Nature, 2025
Keywords
Hand-assisted laparoscopic surgery, Small intestinal neuroendocrine tumours, Open surgery, Radicality, Minimally invasive surgery
National Category
Surgery
Identifiers
urn:nbn:se:uu:diva-553121 (URN)10.1007/s00423-025-03658-z (DOI)001439675400001 ()40047926 (PubMedID)2-s2.0-86000287810 (Scopus ID)
Funder
Swedish Cancer Society
Available from: 2025-03-26 Created: 2025-03-26 Last updated: 2026-04-17Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-9625-1394

Search in DiVA

Show all publications